Transgenic mouse models of hepatitis C virus (HCV) and identification of HCV therapeutics
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 28, 2009
Grant Date -
Nov 27, 2008
app pub date -
Aug 26, 2005
filing date -
Aug 27, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed herein is the discovery of novel NS3/4A compositions with enhanced expression abilities. Embodiments of the invention include codon optimized NS3/4A compositions and compositions with the Semliki forest virus replicon. Additional embodiments include transgenic organisms containing these NS3/4A compositions, methods or using these transgenic mice to screen and refine drugs, and the drugs refined by these methods. Additional embodiments include protease activity dependent molecules that can indicate the presence or absence of a protease inhibitor.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully